• Annexin V-FITC/PI Apoptosis Assay Kit: Workflow, Use, and Ti

  2026-06-05

  The Annexin V-FITC/PI Apoptosis Assay Kit unlocks rapid, precise detection of apoptosis stages, enabling researchers to distinguish early and late apoptotic events with confidence. Explore advanced workflows, real-world troubleshooting, and insights drawn from cutting-edge RCC research to optimize your cell death analyses.

• Annexin V-FITC/PI Apoptosis Assay Kit: Practical Guide

  2026-06-05

  The Annexin V-FITC/PI Apoptosis Assay Kit offers stage-specific detection of apoptotic and necrotic cells using dual fluorescence markers. It is best suited for rapid, research-focused cell death analysis by flow cytometry or fluorescence microscopy. The kit is not intended for diagnostic or clinical decision-making applications.

• AG-126 (Tyrphostin AG-126): Precision ERK1/2 Inhibition Work

  2026-06-04

  AG-126 (Tyrphostin AG-126) offers selective, protocol-ready ERK1/2 inhibition for dissecting MAPK/ERK pathway dynamics in neuroinflammation and repetitive behavior models. Its proven performance in both in vitro and in vivo workflows makes it an essential tool for researchers modeling cytokine signaling, neuronal activation, and behavioral phenotypes.

• BCA Protein Assay Kit: Precision Protein Quantification Beyo

  2026-06-04

  Explore how the BCA Protein Assay Kit enables sensitive and robust bicinchoninic acid protein quantification for diverse molecular biology applications. This article reveals assay mechanisms, protocol nuances, and unique insights from respiratory cell research, offering depth beyond neurovascular workflows.

• Targeting Fructose Metabolism in Cancer: Role of Aldose Redu

  2026-06-03

  The referenced Cancer Letters study establishes fructose metabolism, specifically the polyol pathway and aldose reductase (AKR1B1), as central drivers of cancer malignancy and poor outcomes. These findings highlight new therapeutic strategies targeting metabolic reprogramming in aggressive tumors, providing a framework for translational research in oncology and metabolic disease.

• Amitriptyline HCl (B2231): Protocols and Best Practices

  2026-06-03

  Amitriptyline HCl is a potent tricyclic compound widely used in neuropharmacology research for selective neurotransmitter receptor modulation. It is best suited for receptor binding assays, cell-based models, and studies on mood and neurodegenerative disorders where reproducibility and specificity are critical. The compound is not recommended for workflows requiring long-term storage of prepared solutions or for mechanistic claims beyond those established by its documented receptor affinities.

• Dynamic ER Translocon Assembly for Multipass Membrane Protei

  2026-06-02

  This study reveals how the endoplasmic reticulum (ER) translocon dynamically assembles specialized complexes in response to the synthesis of multipass membrane proteins. By defining the composition, recruitment, and functional significance of the multipass translocon, the research advances understanding of how the ER tailors its machinery for complex membrane protein biogenesis.

• Suhuang Capsule Inhibits NLRP3 Inflammasome via ER Stress in

  2026-06-02

  This study reveals that Suhuang antitussive capsule alleviates pulmonary dysfunction in cough variant asthma (CVA) by disrupting ER stress-mediated activation of the NLRP3 inflammasome through the RIP1-RIP3-Drp1 signaling axis. These mechanistic insights provide a foundation for future research targeting necroptosis and inflammasome pathways in chronic airway diseases.

• Sulfaphenazole: Precision CYP2C9 Inhibitor for Workflow Inno

  2026-06-01

  Sulfaphenazole delivers best-in-class selectivity as a CYP2C9 inhibitor, bridging drug metabolism modulation with translational vascular and antibacterial research. Its reproducible performance and optimized solubility solutions streamline complex workflows from enzyme inhibition to oxidative stress reduction in tissue repair models.

• Applied ddhCTP: Precision Disruption of Viral RNA Synthesis

  2026-06-01

  Leverage ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP) for robust, mechanism-driven inhibition of RNA virus replication in advanced antiviral assays. This guide delivers stepwise workflows, expert troubleshooting, and translational insights, empowering labs to accelerate antiviral drug discovery with confidence and reproducibility.

• BRCA2 and Nascent Strand Maturation Under PARP Inhibition

  2026-05-31

  This study uncovers a BRCA2-dependent mechanism that rescues nascent DNA strand maturation when PARP activity is blocked by olaparib, revealing how BRCA2 and RAD51 support genome stability beyond canonical repair roles. The findings refine our understanding of DNA damage response in proliferating cells and inform the design of targeted assays and cancer models.

• Erastin as a Precision Ferroptosis Inducer in Cancer Biology

  2026-05-30

  Erastin is a validated ferroptosis inducer that enables targeted, iron-dependent cell death in RAS/BRAF-mutant tumor cells. This guide details optimized protocols, advanced applications, and troubleshooting strategies to maximize experimental reliability and insight for cancer biology research.

• Dose- and Time-Dependent Neurotoxicity of Ibotenic Acid in M

  2026-05-29

  This study systematically characterizes the acute neurotoxic effects of ibotenic acid in mice, revealing a distinct dose- and time-dependent toxicity profile. The findings offer new in vivo insights into early neuronal injury markers, supporting the refinement of neurodegenerative disease models and informing clinical strategies for mushroom poisoning.

• O-GlcNAcylation in Wnt-Stimulated Bone Formation and Glycoly

  2026-05-29

  This paper identifies O-GlcNAcylation as a critical mediator in Wnt3a-induced bone formation, linking post-translational modification to metabolic rewiring in osteoblasts. The findings clarify the dual mechanisms of Wnt signaling in promoting aerobic glycolysis and osteogenesis, offering new directions for targeted bone anabolic therapies.

• Folate-Targeted Nanoactivators Induce Ferroptosis in Pancrea

  2026-05-28

  Gupta et al. 2025 introduce radiocleavable, folate-functionalized rare-earth nanoparticles as a targeted approach to trigger ferroptosis and immunogenic cell death in pancreatic cancer. This strategy remodels the tumor microenvironment and suggests a route to overcoming chemoresistance in dense, poorly vascularized tumors.

12954 records 1/864 page Next 12345 下5页 Last page